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Maurocalcine (MCa) is a 33-amino acid residue peptide that was initially identified in the Tunisian scorpion Scorpio maurus palmatus. This
peptide triggers interest for three main reasons. First, it helps unravelling the mechanistic basis of Ca2+ mobilization from the sarcoplasmic
reticulum because of its sequence homology with a calcium channel domain involved in excitation–contraction coupling. Second, it shows potent
pharmacological properties because of its ability to activate the ryanodine receptor. Finally, it is of technological value because of its ability to
carry cell-impermeable compounds across the plasma membrane. Herein, we characterized the molecular determinants that underlie the
pharmacological and cell-penetrating properties of maurocalcine. We identify several key amino acid residues of the peptide that will help the
design of cell-penetrating analogues devoid of pharmacological activity and cell toxicity. Close examination of the determinants underlying cell
penetration of maurocalcine reveals that basic amino acid residues are required for an interaction with negatively charged lipids of the plasma
membrane. Maurocalcine analogues that penetrate better have also stronger interaction with negatively charged lipids. Conversely, less effective
analogues present a diminished ability to interact with these lipids. These findings will also help the design of still more potent cell penetrating
analogues of maurocalcine.
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Maurocalcine (MCa) is a 33-amino acid residue peptide that
originates from the venom of the chactid scorpion Scorpio
maurus palmatus [1]. It can be produced by chemical synthesis
without structural alteration [1]. The solution structure of MCa,
as defined by 1H-NMR, displays an inhibitor cystine knot motif
[2] containing threeβ-strands (strand 1 from amino acid residues
9 to 11, strand 2 from 20 to 23, and strand 3 from 30 to 33). Both
β-strands 2 and 3 form an antiparallel sheet. The folded/oxidized
peptide contains three disulfide bridges arranged according to
the pattern: Cys3–Cys17, Cys10–Cys21 and Cys16–Cys32 [1].
MCa now belongs to a family of scorpion toxins since it has
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Pandinus imperator (82% identity; [3]) and with both opicalcine
1 and 2 from the scorpion Opistophthalmus carinatus (91 and
88% identities, respectively, [4]).
MCa and its structurally related analogues trigger interest for
three main reasons. First, MCa is a powerful activator of the
ryanodine receptor (RyR), thereby triggering calcium release from
intracellular stores [5,6]. MCa binds with nanomolar affinity onto
RyR, a calcium channel from the sarcoplasmic reticulum (SR),
and generates greater channel opening probability interspersed
with long-lasting openings in a mode of sub-conductance state
[1]. Second, MCa has a unique sequence homology with a cyto-
plasmic domain (termed domain A) of the pore-forming subunit
of the skeletal muscle dihydropyridine (DHP)-sensitive voltage-
gated calcium channel (DHP receptor, DHPR). This homology
implicates a DHPR region that is well known for its involvement
in the mechanical coupling between the DHPR and RyR, a
process whereby a modification in membrane potential is sensed
by the DHPR, transmitted to RyR, and produces internal calcium
release followed by muscle contraction. It is therefore expected
that a close examination of the cellular effects of MCa on the
process of excitation–contraction coupling may reveal intimate
details of the mechanistic aspects linking the functioning of the
DHPR to that of RyR. In that sense, a role of domain A in the
termination of calcium release upon membrane repolarisation has
been proposed through the use of MCa [7]. Third, MCa appears
unique in the field of scorpion toxins for its ability to cross the
plasma membrane. Application of MCa in the extracellular
medium of cultured myocytes triggers a transient calcium release
from the SR intracellular store within seconds suggesting a very
fast passage across themembrane [5]. The identification ofMCa’s
binding site on RyR and the cytoplasmic localization of this site
indicate that MCa crosses the plasma membrane to reach the
cytoplasm of the cell [8]. To demonstrate the ability of MCa to
cross the plasma membrane, a biotinylated derivative of MCa
(MCab) was synthesized, coupled to a fluorescent derivative of
streptavidine, and the entire complex was shown to reach the
cytoplasmofmany cell types [9,10]. This cell penetration does not
require metabolic energy but endocytosis cannot be ruled out. It is
rapid, reaches saturation within minutes, is dependent on the
transmembrane potential and occurs at concentrations as low as
10 nM [10]. Cell penetration of a large protein such as
streptavidine indicates that MCa can be used as a vector for the
cell penetration of cell impermeable compounds. This raises
considerable technological interest in the peptide.
Considering its characteristics, it makes no doubt that it now
belongs to the structurally unrelated family of cell-penetrating
peptides (CPPs). Known CPPs include the HIV-encoded
transactivator of transcription (Tat) [11], the insect transcription
factor Antennapedia (Antp or penetratin) [12], the herpes virus
protein VP22, a transcription regulator, the chimeric peptide
transportan [13] made in part by the neuropeptide galanin and by
the wasp venom peptide mastoparan, and polyarginine peptides
[14]. The only structural feature that MCa has in common with
these other CPPs is the presence of a large basic domain. Indeed,
MCa carries a net positive charge of +8, 12 residues out of 33 are
basic, and the electrostatic surface potential of MCa indicatesthat it presents a basic face involving the first amino terminal Gly
residue and all Lys residues of the peptide. CPPs are efficient
vectors for the cell penetration of oligonucleotides [15],
plasmids [16], antisense peptide nucleic acids [17], peptides
[18], proteins [19,20], liposomes [21] and nanoparticles [22]. As
such, CPPs appear invaluable for numerous medical, technolo-
gical and diagnostic applications.
Because of the potential of MCa to deliver membrane im-
permeable compounds without signs of cell toxicity, and con-
sidering its efficiency at low concentrations, it appears essential
to define new analogues that lack the pharmacological effects of
wild-type MCa but preserve or enhance its cell penetration
efficiencies. Several new mutated analogues were chemically
synthesized, and assessed for their effects on RyR and their
penetration efficiencies, as well as compared for their toxicity on
primary cultures of neurons. Finally, these analogues were also
evaluated for their ability to interact with membrane lipids that
are presumed to be implicated in the cell penetration of CPPs.
The data obtained indicate that monosubstitution of amino acids
can improve MCa’s ability to penetrate within cells and further
decrease the neuronal toxicity of the peptide. They confirm the
contribution of the basic amino acid residues in cell penetration
and provide new leads for the synthesis of peptide analogues
devoid of pharmacological effects.
2. Materials and methods
2.1. Chemical synthesis of biotinylated maurocalcine and
point-mutated analogues
N-α-fluorenylmethyloxycarbonyl (Fmoc) L-amino acids, 4-hydroxymethyl-
phenyloxy (HMP) resin, and reagents used for peptide synthesis were obtained
from Perkin-Elmer. N-α-Fmoc-L-Lys(Biotin)-OH was purchased from Neosys-
tem group SNPE. Solvents were analytical grade products from Carlo Erba-SDS
(Peypin, France). Biotinylated MCa (MCab) and its biotinylated point-mutated
analogues were obtained by the solid-phase method [23] using an automated
peptide synthesizer (Model 433A, Applied Biosystems Inc.). Sixteen different
analogues were designed such that Ala replaced a native amino acid of MCa
(Fig. 1). Peptide chains were assembled stepwise on 0.25 mEq of hydro-
xymethylphenyloxy resin (1% cross-linked; 0.77 mEq of amino group/g) using
1 mmol of N-α-Fmoc amino acid derivatives. The side chain-protecting groups
were: trityl for Cys and Asn; tert-bytyl for Ser, Thr, Glu, and Asp;
pentamethylchroman for Arg, and tert-butyloxycarbonyl or Biotin for Lys.
N-α-amino groups were deprotected by treatment with 18% and 20% (v/v)
piperidine/N-methylpyrrolidone for 3 and 8 min, respectively. The Fmoc-amino
acid derivatives were coupled (20 min) as their hydroxybenzotriazole active
esters in N-methylpyrrolidone (4 fold excess). After peptide chain assembly, the
peptide resin was treated between 2 and 3 h at room temperature, in constant
shaking, with a mixture of trifluoroacetic acid (TFA)/H2O/thioanisol/ethane-
dithiol (88/5/5/2, v/v) in the presence of crystalline phenol (2.25 g). The peptide
mixture was then filtered, and the filtrate was precipitated by adding cold
t-butylmethyl ether. The crude peptide was pelleted by centrifugation (3000×g;
10 min) and the supernatant was discarded. The reduced peptide was then
dissolved in 200mMTris–HCl buffer, pH 8.3, at a final concentration of 2.5 mM
and stirred under air to allow oxidation/folding (between 50 and 72 h, room
temperature). The target products, MCab and its analogues, were purified to
homogeneity, first by reversed-phase high pressure liquid chromatography,
HPLC, (Perkin-Elmer, C18 Aquapore ODS 20 μm, 250×10 mm) by means of a
60-min linear gradient of 0.08% (v/v) TFA/0-–30% acetonitrile in 0.1% (v/v)
TFA/H2O at a flow rate of 6 ml/min (λ=230 nm). The homogeneity and identity
of the peptides were assessed by: (i) analytical C18 reversed-phaseHPLC (Merck,
C18 Li-chrospher 5 μm, 4×200 mm) using a 60-min linear gradient of 0.08%
(v/v) TFA/0–60% acetonitrile in 0.1% (v/v) TFA/H2O at a flow rate of 1 ml/min;
Fig. 1. Amino acid sequences of MCa and of its biotinylated analogues. Amino acid residues are described by single letter code. Kb=biotinylated version of lysine
residue. The net global charge of the molecule is provided for each MCa analogue.
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N2 atmosphere); and (iii) mass determination by matrix assisted laser desorption
ionization–time of flight mass spectrometry.
2.2. Conformational analyses of MCa, MCa E12A, MCa K20A and
MCa R24A by circular dichroism
Circular dichroism (CD) spectra were recorded on a Jasco 810 dichrograph
using 1-mm-thick quartz cells. Spectra were recorded between 180 and 260 nm
at 0.2 nm/min and were averaged from three independent acquisitions. The
spectra were corrected for water signal and smoothed by using a third-order least
squares polynomial fit.
2.3. Preparation of heavy SR vesicles
Heavy SR vesicles were prepared following the method of Kim et al. [24]
modified as described previously [25]. Protein concentration was measured by
the Biuret method.
2.4. [3H]-ryanodine binding assay
Heavy SR vesicles (1 mg/ml) were incubated at 37 °C for 3 h in an assay
buffer composed of 5 nM [3H]-ryanodine, 150 mM NaCl, 2 mM EGTA,
2 mM CaCl2 (pCa=5), and 20 mM HEPES, pH 7.4. Wild-type or mutant
MCab was added to the assay buffer just prior the addition of heavy SR
vesicles. [3H]-ryanodine bound to heavy SR vesicles was measured by fil-
tration through Whatmann GF/B glass filters followed by three washes with
5 ml of ice-cold washing buffer composed of 150 mM NaCl, 20 mM HEPES,
pH 7.4. Filters were then soaked overnight in 10 ml scintillation cocktail
(Cybscint, ICN) and bound radioactivity determined by scintillation spectro-
metry. Non-specific binding was measured in the presence of 20 μM cold
ryanodine. Each experiment was performed in triplicate and repeated at least
two times. All data are presented as mean±S.D.
2.5. Cell culture
Chinese hamster ovary (CHO) cell line (from ATCC) were maintained at
37 °C in 5% CO2 in F-12K nutrient medium (InVitrogen) supplemented with
10% (v/v) heat-inactivated foetal bovine serum (InVitrogen) and 10,000 units/ml
streptomycine and penicillin (InVitrogen).2.6. Primary culture of cerebellar granule neurons
Media used for the culture of cerebellar granule neurons (CGN) was based
on Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) containing
10 unit/ml penicillin, 10 μg/ml streptomycin, 2 mM L-glutamine, and 10 mM
HEPES (K5 medium). KCl was added to a final concentration of 25 mM (K25
medium) and supplemented with 10% fetal bovine serum (K25+S medium).
Primary cultures of CGN were prepared from 6-day-old S/IOPS NMRI mice
(Charles River Laboratories), as described previously [26,27] with some
modifications. The cerebella were removed, cleared of their meninges, and cut
into 1-mm pieces. They were then incubated at 37 °C for 10 min in 0.25%
trypsin-EDTA (Invitrogen) in DMEM. An equal volume of K25+S medium and
3000 units/ml DNase I (Sigma) were added before dissociation by triturating
using flame-polished Pasteur pipettes. Next, an equal volume of DMEM
containing trypsin inhibitor (Sigma) and 300 units/ml DNase I were added to the
cells. Dissociated cells were centrifuged for 5 min at 500×g. The pellet was
resuspended in fresh K25+S medium and cells were plated onto poly-D-lysine
(10 μg/ml, Sigma) precoated 96-well plates at a density of 8×104 cells/well. The
cerebellar granule neurons were grown in K25+S medium in a humidified
incubator with 5% CO2 / 95% air at 37°C. Cytosine-β-D-arabinoside (10 μM,
Sigma) was added after 1 day in vitro to prevent the growth of non-neuronal
cells.
2.7. MTT assay
Primary cultures of CGN were seeded into 96 well micro plates at a density
of approximately 8×104 cells/well. After 4 days of culture, the cells were
incubated for 24 h at 37 °C with MCab or its analogues at a concentration of 1 or
10 μM. Control wells containing cell culture medium alone or with cells, both
without peptide addition, were included in each experiment. The cells were then
incubated with 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide
(MTT) for 30 min. Conversion of MTT into purple colored MTT formazan by
the living cells indicates the extent of cell viability. The crystals were dissolved
with dimethyl sulfoxide (DMSO) and the optical density was measured at
540 nm using a microplate reader (Biotek ELx-800, Mandel Scientific Inc.) for
quantification of cell viability. All assays were run in triplicates.
2.8. Membrane integrity LDH assay
A lactate dehydrogenase (LDH) assay was used to probe membrane integrity
disturbance by MCa, MCa E12A and MCa K20A according to the protocol
Table 1
Effect of MCab and its analogues on the parameters of [
3H]-ryanodine binding
onto SR vesicles
MCa analogue EC50 (nM) Binding stimulation
(x-fold)
MCa 25.2±2.1 16.7
MCab 35.2±7.5 17.9
MCab D2A 10.3±0.7 17.6
MCab L4A 28.8±6.1 15.0
MCab P5A 9.0±1.2 17.5
MCab H6A 29.4±3.2 16.6
MCab L7A 74.9±3.6 7.1
MCab K8A 104.3±13.3 10.1
MCab L9A 17.3±1.2 18.2
MCab E12A 7.3±0.4 15.7
MCab N13A 13.8±1.4 14.6
MCab D15A 9.5±1.1 14.1
MCab K19A 71.0±8.1 12.2
MCab K20A 114.5±14.3 9.4
MCab K22A 162.6±18.7 5.1
MCa R23A 302.5±62.1 4.5
MCab R24A N1000 1.1
MCa T26A 121.1±33.0 13.7
The EC50 values and stimulation factors are obtained from the fit of the data
shown in Fig. 2.
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were incubated with 10 μM peptide for 24 h, then 30 min at 22 °C, a volume of
CytoTox-ONE™ reagent was added, mixed and incubated at 22 °C for 10 min,
50 μl of STOP solution added, and the fluorescence was measured (excitation
wavelength of 560 nm and emission at 590 nm). Control experiments were also
performed to measure background LDH release in the absence of the peptide,
and also maximal release of LDH after total cell lysis. Percentage of cell toxicity
is measured as follows: 100×(Experimental with peptide−cultured media
background) / (maximal LDH release−cultured media background).
2.9. Formation of MCab (wild-type or mutant)/streptavidin–cyanine
complex
Soluble streptavidine–cyanine 5 or streptavidine–cyanine 3 (Strep-Cy5 or
Strep-Cy3, Amersham Biosciences) was mixed with four molar equivalents of
wild-type or mutant MCab 2 h at 37 °C in the dark in PBS (phosphate-buffered
saline) (in mM): NaCl 136, Na2HPO4 4.3, KH2PO4 1.47, KCl 2.6, CaCl2 1,
MgCl2 0.5, pH 7.2.
2.10. Flow cytometry
Wild-type or mutant MCab–Strep-Cy5/Cy3 complexes were incubated for
2 h with live cells to allow cell penetration to occur. The cells were then washed
twice with PBS to remove the excess extracellular complexes. Next the cells were
treated with 1 mg/ml trypsin (InVitrogen) for 10 min at 37 °C to remove
remaining membrane-associated extracellular cell surface-bound complexes.
After trypsin incubation, the cell suspension was centrifuged at 500×g and
suspended in PBS. Flow cytometry analyses were performedwith live cells using
a Becton Dickinson FACSCalibur flow cytometer (BD Biosciences). Data were
obtained and analyzed using CellQuest software (BD Biosciences). Live cells
were gated by forward/side scattering from a total of 10,000 events.
2.11. Confocal microscopy and immunocytochemistry
For analysis of the subcellular localization of wild-type or mutant MCab–
Strep-Cy3/Cy5 complexes in living cells, cells were incubated with the
complexes for 2 h, and then washed with DMEM alone. Immediately after
washing, the nucleus was stained with 1 μg/ml dihydroethidium (DHE,
Molecular probes, USA) for 20 min, and then washed again with DMEM. DHE
shows a blue fluorescence (absorption/emission: 355/420 nm) in the cytoplasm
of cells until oxidization to form ethidium which becomes red fluorescent
(absorption/emission: 518/605 nm) upon DNA intercalation. Only the red
fluorescence was measured in the nucleus. After this step, the plasma membrane
was stained with 5 μg/ml FITC-conjugated Concanavalin A (Molecular Probes)
for 3 min. Cells were washed once more, but with PBS. Live cells were then
immediately analyzed by confocal laser scanning microscopy using a Leica
TCS-SP2 operating system. Alexa-488 (FITC, 488 nm) and Cy3 (543 nm) or
Cy5 (642 nm) were sequentially excited and emission fluorescence were
collected in z-confocal planes of 10–15 nm steps. Images were merged in Adobe
Photoshop 7.0.
2.12. Interaction of MCab and its mutants with different lipids
Strips of nitrocellulose membranes containing spots with different
phospholipids and sphingolipids were obtained from Molecular probes.
These membranes were first blocked with TBS-T (150 mM NaCl, 10 mM
Tris–HCl, pH 8.0, 0.1% (v/v) Tween 20) supplemented with 0.1% free bovine
serum albumin (BSA) for about 1 h at room temperature. Later, these
membranes were incubated with 100 nM wild-type or mutant MCab along
with TBS-T and 0.1% free BSA for 2 h at room temperature. Incubation with
100 nM biotin alone was used as a negative control condition. The membranes
were then washed a first time with TBS-T 0.1% free BSA using gentle
agitation for 10 min. Binding of wild-type or mutant MCab onto the lipid
strips was detected by incubating 30 min the lipid strips with 1 μg/ml ready to
use streptavidine horse radish peroxidase (Vector labs, SA-5704). The
membranes were washed a second time with TBS-T 0.1% free BSA. Interaction
was detected by incubating the membranes with horseradish peroxidasesubstrate (Western Lightning, Perkin-Elmer Life Science) for 1 min in each
case followed by exposure to Biomax film (Kodak).
3. Results
3.1. Synthesis of MCa analogues
Fig. 1 illustrates the primary structure of the various
analogues of MCa that were chemically synthesized. Most of
the analogues were biotinylated at their amino-terminus to favor
their coupling to streptavidine. All substitutions were made by
alanine residues. The global net charge of each peptide is also
indicated. Biotinylation does not alter the global net charge of
MCa. Some of the mutated analogues of MCa were reported
previously, but in their non-biotinylated version [5].
3.2. Effects of MCa analogues on [3H]-ryanodine binding to
RyR1
The purpose of this study is to compare the pharmacological
efficacy of various MCa analogues to their efficiency of cell
penetration. The ultimate aim is to help the design of new point
mutated analogues of MCa that can serve as good cell
penetration carriers without displaying an adverse pharmaco-
logical effect once penetrated inside cells. The pharmacological
potential of MCa analogues can be assessed by their efficacy in
stimulating [3H]-ryanodine binding onto RyR1 oligomers from
SR vesicles, an effect that appears linked to the promotion of
opening modes of the channel. Since the analogues synthesized
were biotinylated for the purpose of forming a complex with
fluorescent derivatives of streptavidine, we first compared the
efficacy of [3H]-ryanodine binding stimulation between MCa
and MCab (Table 1). Adding a biotin group to the N-terminus
Fig. 2. Concentration-dependent effect of MCa analogues on [3H]-ryanodine binding to heavy SR vesicles. [3H]-ryanodine binding was measured at pCa 5 (free Ca2+ 10 μM) in the presence of 5 nM [3H]-ryanodine for
3 h at 37 °C. Non specific binding was less than 5% of the total binding and was independent of the concentration of each MCa analogue. Data were fitted with a logistic function of the type y=y0+(a/(1+ (x/EC50)
b))
where y0 is the basal [
3H]-ryanodine binding in the absence of MCa or its analogues, a the maximum achievable binding, b the slope coefficient and EC50 the concentration of half-binding stimulation. Experimental data
for the effect of MCa is shown once (top left binding curve, filled circles) and the fit of these data shown each time as dashed line for the purpose of comparison with each MCa analogue. EC50 values and binding
stimulation factors are provided in Table 1. Data are triplicates. Representative cases of n=3 experiments.
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Fig. 3. Cell penetration of wild-type and mutated MCab in complex with
streptavidine–Cy5 in CHO cells as assessed quantitatively by FACS. The
concentration used for all the analogues is 4 μM combined with 1 μM
streptavidine–Cy5. Cells were incubated 2 h with the complex before being
washed and treated for 10 min with 1 mg/ml trypsin. (A) Comparison of FACS
data on CHO cells for streptavidine–Cy5 alone (control), for MCab K20A, the
least penetrating mutant, for MCab, and for MCab E12A, the most penetrating
analogue. (B) Comparison of mean fluorescence intensity for the cell penetration
of all MCab analogues in CHO cells. The dash represents the mean fluorescence
of cells alone. All data were performed the same day with the same batch of
cells. Representative case of n=3 experiments.
Fig. 4. Mean cell fluorescence intensity as a function of concentration of cell
penetrating complexes. The indicated concentrations are for streptavidine–Cy5
(from 10 nM to 2.5 μM). Streptavidine concentrations higher than 2.5 μM are
toxic to cells when allowed to penetrate and cannot be tested. MCab K20A and
MCab E12A concentrations are fourfold greater than streptavidine–Cy5
concentrations (from 40 nM to 10 μM). The data for MCab E12A could be
fit by a sigmoid function of the type y=a/(1+exp(− (x−PC50)/b)) where a=
2541±108 a.u., the maximal fluorescence intensity, PC50=113±16 nM, the half-
maximal effective penetrating concentration, and b=20.9±17.9. Experiments
were repeated three times.
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3H]-
ryanodine binding stimulation or the stimulation factor
(between 16- and 18-fold). The properties of all the point
mutated analogues of MCab (14 of the 16 mutants) should thus
also be comparable to similar point mutated analogues of MCa
(2 of the 16 mutants). Next, all the mutants were compared
using a similar batch of SR preparation. We noticed that basal
binding of [3H]-ryanodine binding (in the absence of any
analogues) varies greatly with the SR batch although saturation
appears more or less similar. Hence, the stimulation efficacy of
the binding (ratio between stimulated [3H]-ryanodine binding
and basal [3H]-ryanodine binding) also varies with the SR
batch (data not shown). Fig. 2 thus compares the effects of
various point-mutated analogues of MCab onto the [
3H]-
ryanodine binding to SR vesicles from the same batch pre-
paration. The main results are summarized in Table 1. Six
analogues have greater affinity for RyR1 than MCab: MCab
D2A, MCab P5A, MCab L9A, MCab E12A, MCab N13A and
MCab D15A. It is of interest that a greater affinity for RyR1 can
be triggered by mutating negatively charged amino acid
residues that increase the net positive change of MCa from+8 to +9 (Fig. 1). Of note, none of these mutants affected the
binding stimulation factor suggesting that these analogues
behave similarly than MCa and MCab at saturating concentra-
tions. Alanine substitution of many of the positively charged
amino acid residues of MCa that belong to the basic face of the
molecule [10] reduce the affinity of MCa for RyR1. These
residues comprise Lys8, Lys19, Lys20, and Lys22, which
confirms previous findings with similar non-biotinylated
MCa analogues [5]. Mutation of two other positively charged
residues, Arg23 and Arg24, induce similar effects. Besides these
six analogues, MCab L7A and MCab T26A also display a
significant reduction in the affinity of MCab for RyR1. All
MCab analogues that were shown to have reduced affinity for
RyR1 also present reduced potencies of [3H]-ryanodine
binding stimulation (Table 1). A form of correlation appears
to occur between the reduction in affinity and stimulation
efficacy, with the notable exception of MCab T26A that kept a
rather good stimulation efficacy despite a strong reduction in
affinity. Finally, among the sixteen mutants that were tested,
MCab L4A and MCab H6A did neither change the affinity nor
the stimulation efficacy of MCab.
In conclusion, for the purpose of selecting mutated analogues
ofMCa defective in pharmacological effects, mutations at amino
acid positions 7, 23, 24 and 26 appear particularly interesting
since they do not contribute to the presentation of the basic face
of MCa that is presumably required for cell penetration of MCa
[10].
3.3. Effects of point mutations of MCab on its cell penetration
efficiency
To perform a quantitative comparison of the cell penetration
efficacy of the various mutated analogues of MCab, FACS
Fig. 5. Conformational analysis of maurocalcin analogues by circular dichroism.
Far-UV CD spectra of MCa and three of its analogues at 50 μM in pure water
recorded at 20 °C. Each spectrum is the mean of three independent acquisitions.
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were incubated for 2 h with 1 μM of wild-type or mutant MCab/
streptavidine–Cy5 complexes (4 μM of wild-type or mutant
MCab for 1 μM of streptavidine–Cy5) before washing, 10 min
treatment with 1 mg/ml of trypsin, and FACS analysis.
Representative histograms indicating the intensity of cell
fluorescence for wild-type and two mutants MCab/streptavi-
dine–Cy5 complexes are shown in Fig. 3A. MCab K20A
induced a mean cell penetration of streptavidine that was 12.5-
fold less pronounced than wild-type MCab, whereas MCab
E12A increased its cell penetration by a factor of 2.2-fold. A
quantitative comparison of the cell penetration of the various
MCab analogues was performed and is shown in Fig. 3B. Not all
point mutated analogues of MCab behave similarly in terms of
cell penetration, at least at the concentration tested (1 μM) and
for the duration examined (2 h). Besides MCab E12A, two other
mutants provide a better cell penetration than MCab itself
(MCab H6A and MCab K8A). In contrast, two other mutants
almost completely inhibit the cell penetration (MCab K19A and
MCab K20A). Mild reduction in cell penetration efficacy is
observed for MCab L4A, N13A, K22A and R24A (between 1.9-
and 3.2-fold). These data thus indicate that the cell penetration
properties of MCab can be greatly modulated by selective point
mutation of it amino acid sequence. Improved analogues, as
well as less potent derivatives, can be produced using simple
amino acid substitutions.
To determine the reasons that may underlie these differences
in cell penetration efficacies between the various analogues, a
dose–response curve on CHO cells was performed for the most
and the least penetrating analogues, MCab E12A and MCab
K20A, respectively (Fig. 4). As shown, the two mutants differed
in their half-effective concentration for cell penetration efficacyFig. 6. Confocal immunofluorescence images of living CHO cells incubated for 2 h w
K20A. Streptavidine–Cy5 appears in blue, the nucleus in red and the plasma membra
with the MCab analogues but the obvious differences in cell penetration efficiencies.
cells incubated with MCab alone to show that the blue fluorescence observed is only
fluoresce in blue in the cytoplasm (top panel).over a 2-h incubation period. MCab E12A penetrates with a
half-effective concentration of PC50=113±16 nM. In contrast,
MCab K20A penetrates with an estimated half-effective
concentration of PC50=1300–1400 nM. For the MCab K20A
mutant, concentrations higher than 2.5 μM could not be tested
because of cell toxicity of streptavidine. In spite of this toxicity,
it was observed that, at saturating concentrations, the same
maximal amount of streptavidine–Cy5 could be carried into the
cell as with MCab E12A. Therefore, it is possible that the
differences in penetration efficacies, observed between the
various mutated analogues in Fig. 3C, is more linked to
differences in “cell affinity” for one or several membrane
components than to an impairment of the mechanism of cell
penetration. The observation that the cell penetration of MCab
E12A/streptavidine–Cy5 can saturate is an indication that the
process is halted once a form of concentration equilibrium is
reached or that the plasma membrane constituents required for
cell penetration of the complexes are present in finite amounts.
Finally, we also determined whether differences in pharma-
cological effects and cell penetration among various MCa
analogues could be linked to adverse structural alterations
introduced by the point mutations. This was performed by
circular dichroism analyses of wild-type MCa, MCa E12A,
MCa K20A and MCa R24A since these analogues represented
some extreme cases (Fig. 5). As shown, the CD spectra of all
these peptides are fully superimposed. One can thus deduce that
the three analogues possess the same conformation as native
MCa.
3.4. Altered cell penetration efficacies of the MCab analogues
is not associated with differences in cell localization
To check the cell distribution of MCab/streptavidine–Cy5
complexes, it is recommended to work on living cells since
cell fixation has been reported to alter the cell distribution of
various CPPs [28]. As shown in Fig. 6, MCab/streptavidine–
Cy5 complexes are present as punctuate dots in the cytoplasm
of living CHO cells (2 h of incubation with the complex,
wash, staining and immediate observation by confocal
microscopy). The plasma membrane is labeled with con-
canavaline A, whereas the nucleus is stained with DHE. The
distribution of the MCab/streptavidine–Cy5 complex is not
different than the one observed in fixed HEK293 cells [10],
suggesting that, contrary to other CPPs, cell fixation does not
alter the distribution of this particular CPP. With mutated
MCab analogues that penetrate better or less than wild-type
MCab (MCab E12A and MCab K20A), a similar subcellular
distribution of the complex is observed suggesting that the
mechanism of cell penetration is not altered by point mutation
of MCab. Corroborating the FACS experiments, a significant
reduction of complex entry is observed with the MCab K20Aith 1 μM streptavidine–Cy5 in complex with 4 μMMCab, MCab E12A or MCab
ne in green. Note the lack of differences in cell distribution of streptavidine–Cy5
Images are from a single confocal plane. Control images were also included for
due to the presence of streptavidine and is not related to the ability of DHE to
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Fig. 7. Interaction of MCab or mutated analogues with membrane lipids. The MCab analogues were used at a concentration of 100 nM and incubated for 2 h with the
lipid strips. Each dot possesses 100 pmol of lipid immobilized on the strip. Representative examples are shown for MCab, MCab L7A, MCab E12A, MCab K20A and
MCab R24A. (A) Interaction with various phospholipids. The lipids are identified by their numbered positions on the strip (left panel). Numbers refer to:
lysophosphatidic acid (1), lysophosphatidylcholine (2), phosphatidylinositol (Ptdlns) (3), Ptdlns(3)P (4), Ptdlns(4)P (5), Ptdlns(5)P (6), phosphatidylethanolamine (7),
phosphatidylcholine (8), sphingosine 1-phosphate (9), Ptdlns(3,4)P2 (10), Ptdlns(3,5)P2 (11), Ptdlns(4,5)P2 (12), Ptdlns(3,4,5)P3 (13), phosphatidic acid (14),
phosphatidylserine (15), and no lipids (16). (B) Interactions of MCab and mutated analogues with sphingolipids. Numbers refer to: sphingosine (1), sphingosine
1-phosphate (2), phytosphingosine (3), ceramide (4), sphingomyelin (5), sphingosylphosphophocholine (6), lysophosphatidic acid (7), myriocin (8),
monosialoganglioside (9), disialoganglioside (10), sulfatide (11), sphingosylgalactoside (12), cholesterol (13), lysophosphatidyl choline (14), phosphatidylcholine
(15), and blank (16).
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E12A mutant. Similar observations were made in HEK293
cells, 3T3 cells, hippocampal and DRG neurons (unpublished
observations).
3.5. Differential interaction of MCab and its analogues with
negatively charged lipids
For a direct membrane translocation of MCa into cells, a
process whereby the peptide would flip from the outer face of
the plasma membrane to the inner face, then released free into
the cytoplasm, the peptide should interact with various lipids of
the membrane, preferably negatively charged ones. These
interactions were challenged by incubating 100 nM of MCab
with lipid strips from Molecular Probes. The immobilized
peptide was then revealed with streptavidine–horse radish
peroxidase (HRP). MCab was found to strongly interact with
phosphatidylinositol (PtdIns)(3)P, PtdIns(4)P, PtdIns(5)P, phos-
phatidic acid and sulfatide, and more weakly with lysopho-sphatidic acid, PtdIns(3,5)P2 and phosphatidylserine (Fig. 7,
Table 2). These are all negatively charged lipids. In contrast, at
100 nM, it does not interact with lysophosphatidylcholine,
phosphatidylcholine, sphingosine, sphingosine 1-phosphate,
phytosphingosine, ceramide, sphingomyelin, sphingosylpho-
sphocholine, myriocin, monosialoganglioside, disialoganglio-
side, sphingosylgalactoside, cholesterol, lysophosphatidyl
choline, or phosphatidylcholine (Fig. 7). As control experiment,
100 nM biotin was probed alone and no interaction was found
with any of the lipids (data not shown). In comparison with
wild-type MCab and of all the MCab mutants tested, two
mutants displayed a new lipid interaction with PtdIns (MCab
L4A and MCab L7A) and four mutants with PtdIns(4,5)P2
(MCab D2A, MCab L4A, MCab H6A and MCab N13A). These
new interactions were mostly weak, except for MCab L4Awith
PtdIns(4,5)P2. In contrast, many of the weak lipid interactions
of MCab were lost as a result of various mutations. This is the
case for the interactions with lysophosphatidic acid, PtdIns(3,5)
P2 and phosphatidylserine, although it should be mentioned that
Table 2
Strength of lipid interactions for MCab and its analogues
MCab and
analogues
Lysophosphatidic
acid
Phosphatidylinositol
(Ptdlns)
Ptdlns
(3)P
Ptdlns
(4)P
Ptdlns
(5)P
Ptdlns
(3,5)P2
Ptdlns
(4,5)P2
Phosphatidic
acid
Phosphatidylserine Sulfatide
MCab + ++ ++ ++ + ++ + ++
MCab D2A + ++ ++ ++ ++ + ++ ++
MCab L4A + ++ ++ ++ ++ ++ + ++
MCab P5A ++ + ++ ++ + ++
MCab H6A + ++ ++ ++ + ++ + ++
MCab L7A + ++ ++ ++ ++ ++ + ++
MCab K8A + + + ++ + + ++
MCab L9A +++ +++ +++ ++ ++ +++
MCab E12A +++ +++ +++ ++ +++ +++
MCab N13A ++ ++ ++ + ++ + ++
MCab D15A ++ ++ ++ ++
MCab K19A ++ ++ +
MCab K20A ++ +
MCab K22A + + + + + +
MCab R24A ++ + + ++
Experimental conditions as described in the legend of Fig. 6.
(+++) very strong interaction (++) strong interaction (+) weak interaction.
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Although it is difficult to correlate specific lipid interactions
with the strength of cell penetration, some basic conclusions canFig. 8. Neuronal toxicity of MCa and mutated analogues. Peptides were tested alon
interference contrast) illustrating cerebellar granule cells in primary culture before (0 h
17h incubation period with either 1 or 10 μMMCa or one of its mutated biotinylated
These experiments were repeated three times, data shown as triplicates. Significance
asterisks). (C) Cell toxicity effect of 10 μM MCa, MCa E12A or MCa K20A incubbe reached. The MCab E12A mutant displayed the strongest
lipid interactions of all mutants, which is probably at the basis of
its better cell penetration properties. In contrast, both MCabe without coupling to streptavidine. (A) Transmitted light images (differential
) and after (17 h) incubation with 1 or 10 μMMCa. (B) Neuronal survival after a
analogue as assessed by the MTT test. MCa and MCab produced similar results.
is provided as a deviation of three times the SD value from 100% (denoted as
ated 24 h with CHO cells as measured by LDH release.
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properties, also displayed the poorest repertoire of lipid
interaction and/or the weakest interactions. Further detailed
lipid pharmacology combined with FACS analysis will be
required to determine the identity of the lipid(s) that are essential
for an efficient cell penetration of MCa.
3.6. Cell toxicity of MCab and mutated analogues
MCa was shown to be non-toxic to HEK293 cells for
incubation periods of 24 h and at concentrations up to 5 μM
[10]. Since HEK293 cells might be more resistant to toxic
agents than cells from primary origin, the effect of MCab and
mutated analogues were also tested on the survival rate of
cerebellar granule cells maintained in primary culture (Fig. 8).
As seen, no cell toxicity could be observed by transmitted light
microscopy for a 17-h incubation period with 1 or 10 μM MCa
(Fig. 8A). However, using the more sensitive MTT assay, MCa
produced 16.0±2.8% cell toxicity at 1 μM. The biotinylated
analogue of MCa, MCab, behaved similarly to MCa (not shown)
suggesting that biotinylated and non-biotinylated analogues
could be compared among each others. However, most MCab
analogues showed either no neuronal toxicity or limited toxicity
at a concentration of 1 μM (Fig. 8B). Incubation of neuronal
cells with a higher concentration of MCa (10 μM) produced
greater cell death (30.4±17.6%). Similar neuronal survival
percentages were obtained for MCab H6A, MCab K8A, MCab
K22A and MCab R24A. At 10 μM however, most other
peptides remained non-toxic including many of the best cell-
penetrating analogues such as MCab D2A, MCab P5A, MCab
L7A, MCab L9A, MCab E12A and MCab D15A. In conclusion,
most MCab analogues show almost no toxicity on neurons
provided that they are used at 1 μM, a concentration range that
displays a very significant extent of cell penetration for most
mutants in complex with streptavidine. Higher concentrations
can still be used without adverse effects for several analogues of
MCa. Since the peptides interact with the cell membrane lipids,
we determined whether some representative peptides could
have any effect on cell membrane integrity by assessing LDH
release from cells (Fig. 8C). As seen, no greater LDH release is
produced by a 24-h incubation of 10 μM MCa, MCa E12A or
MCa K20A with CHO cells than expected from limited cell
toxicity at this concentration.
4. Discussion
4.1. Cell toxicity and pharmacological profile of MCa
MCa is a potent activator of RyR. As such, it has the
potential to influence Ca2+ homeostasis in each cell type that
expresses a RyR channel. In spite of its effect on Ca2+
mobilization from intracellular stores, MCa presents limited cell
toxicity. No toxicity has been observed on CHO cells or on
HEK293 cells, possibly because of the absence of expression of
RyR [10]. Cell toxicity can be detected to a very limited extent
on primary cultures of cerebellar granule cells, in which the
presence of RyR is known, but it is difficult to correlate thistoxicity to the pharmacological action of the peptide. Indeed, a
similar limited toxicity is apparent at concentrations above 1
μM for the MCa R24A mutant that has not the ability to
mobilize Ca2+ from SR [9], whereas, in contrast, the MCa E12A
mutant, that stimulates [3H]-ryanodine binding onto RyR1 at
lower concentrations than MCa, does not display any sign of
cell toxicity at 10 μM. It should be emphasized that neurons are
more likely to express the RyR2 and RyR3 isoforms than the
RyR1 isoform tested herein. Since neither the pharmacological
action of MCa onto these two isoforms, nor the key residues
responsible for this potential effect, have been determined, it
remains difficult to make a precise correlation between a key
amino acid residue of MCa and some adverse effect on neuronal
survival. Nevertheless, several conclusions are within reach for
the design of an efficient drug carrier based on MCa’s sequence.
First, it is highly desirable to develop a carrier that is devoid of
effect on any of the RyR isoforms, particularly with regard to
Ca2+ mobilization. The partial alanine scan we performed on the
sequence of MCa reveals that this goal is largely accessible
experimentally. Further mutations may be planned, and more
extensive tests will be required on the two other RyR isoforms,
but it is clear that many key residues already represent starting
leads for the rationale design of pharmacologically inert
analogues of MCa. The amino acid residues of interest include
L7, K8, K19, K20, K22, R23, R24 and T26, which represents a
sufficiently diverse array of workable opportunities. Second,
developing a cell penetrating analogue of MCa that is devoid of
cell toxicity is also clearly within reach. Most analogues were
non-toxic to neurons, and many other appear as efficient protein
carriers when used at concentrations well below the toxic
concentration. For instance, the MCa E12A mutant is
maximally effective in carrying streptavidine into cells when
used at a concentration of 250 nM, whereas it is non-toxic even
at 10 μM. Among the pharmacologically least active analogues
devoid of cell toxicity, we can mention those that are mutated at
position L7, K19, K20, R23 and T26. This still represents
sufficient diversity for the design of numerous novel cell
penetrating analogues lacking both pharmacological activity
and signs of cell toxicity. Third, taking into account the two
above-mentioned criteria, lack of pharmacological activity and
lack of cell toxicity, any novel analogue designed should keep
potent cell penetration efficiency. Among the residues of
interest in terms of pharmacology (L7, K19, K20, R23 and
T26), we tested three of them for their penetration efficiency
(L7, K19 and K20). Only the L7 locus appears as an interesting
lead position since the MCa L7A mutant displays an efficient
cell penetration. The L7A being a rather conservative substitu-
tion, the strong impact it displays on the pharmacology of MCa
is quite encouraging. It seems very likely that less conservative
substitutions at this position should further impact the
pharmacology without impairing cell penetration. It should be
mentioned also that for the design of novel potent analogues, an
alternative strategy to a mono substitution would be to perform
several substitution at a time: one that impairs the pharmaco-
logical impact of MCa and shows a lack of toxicity, combined
with another that has improved cell penetration efficiency.
Obviously, this study illustrates that many leading strategies can
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competent analogues of MCa. Further development of a potent
MCa analogue will also be based on the chemical strategies for
coupling MCa to cargoes. As such, the recent finding that a
MCa analogue devoid of internal cysteine residues, required for
the disulfide bridges formation, penetrates into cells, is of great
interest if N-terminal cysteine chemistry is pursued as coupling
strategy (data not shown).
4.2. The molecular determinants of MCa implicated in
pharmacology and cell penetration overlap partially
A peptide that (i) has homology with a calcium channel
sequence (domain A of the II–III loop of Cav1.1), (ii) acts as a
pharmacological activator of RyR, and (iii) penetrates efficiently
into cells by crossing the plasma membrane puts considerable
stringency on its primary structure. Proof of this fact comes from
a sequence comparison with MCa related peptide (IpTx A,
opicalcine 1 and opicalcine 2) that demonstrates very little
sequence variation. Amino acid residues of MCa analogous to
domain A include K19, K20, K22, R23, R24, and T26.
Absolutely all these residues are essential for the pharmacolo-
gical effect of MCa, even though they are not solely implicated
in the recognition of RyR. A similar residue profile appears to
exist for the interaction of MCa with negatively charged lipids
(Table 2) and for cell penetration (Fig. 3), although R23 and T26
mutants were not tested. Undoubtedly, the most prominent
effects were observed for K19 and K20 mutations, with milder
effects for K22 and R24 mutations, suggesting that cell
penetration was less deeply hampered by single point mutations
of MCa residues that are analogous to those of domain A. Proof
that structural divergence exists between MCa and domain A is
the observation that domain A is unable to penetrate into cells in
spite of its homology by the presence of basic residues (data not
shown). The structural requirements for the cell penetration
efficiency of MCa are less stringent than those involved in the
pharmacological effect of the peptide. This is in line with what is
known on other CPPs, with the main structural requirement
being the presence of a basic surface for an efficient cell
penetration. This lower stringency is also in line with the
considerations developed above on the fact that it should be
feasible to uncouple both properties by developing peptide
analogues devoid of pharmacological effects but keeping
considerable cell penetration efficiencies. Nevertheless, a
particular mention should be made to the fact that each mutation
of MCa that increases the net positive charge of the peptide
(D2A, D15A and E12A), all improve the EC50 effect on [
3H]-
ryanodine binding. This may implicate that the nature of the
interaction between MCa and its binding site on RyR is
electrostatic. In the RyR sites identified for the binding of
domain A orMCa, there is indeed a stretch of negatively charged
amino acid residues within site F7.2 that look as promising
candidates for the interaction [8]. Further experimental workwill
be required to test out this hypothesis. Only one of the mutations
of the negatively charged residues of MCa (E12A and not D2A
or D15A) contributes to an improved cell penetration when
tested at a micromolar concentration. But since the E12Amutantalso displays an improved dose–response curve for cell
penetration, similar dose–responses will need to be performed
in order to really efficiently compare the cell penetration potency
of MCa D2A and MCa D15A. Conversely, the K8A mutation
induces a slightly better cell penetration, also indicating that
increasing the net global positive charges of the molecule is not a
prerequisite for a better penetration. Since this mutation
increases the dipole moment of the molecule, this may better
explain the greater potential of this analogue.
4.3. A correlation appears to exist between the strength of lipid
interaction and the potency of cell penetration of MCa’s
analogues
The mechanism of cell penetration of CPPs is not well
dissected. Two modes of cell penetration have been proposed.
One involves a direct interaction of CPPs with charged heparan
sulfates present at the cell surface, followed by macropinocy-
tosis. Delivery into the cytoplasm would be partial and would
occur from late endosomes. A second one implies a direct
interaction of the CPPs with negatively charged lipids, followed
by a translocation mechanism that delivers the penetrating
peptide and its cargo into the cytoplasm. Both modes are not
contradictory and may well coexist in a variety of cell types.
Also, the concept that one set of interactions directs the mode of
penetration (lipids for translocation, and heparin sulfates for a
form of endocytosis) is by itself unproven. Herein, we have
further examined the interaction of MCa and mutated analogues
with several lipids. The observations made are coherent with the
presence of a basic surface on MCa. The peptides interact well
with many negatively charged lipids which is a prerequisite for
a mechanism of penetration that is based on membrane
translocation. Among all the lipids identified, it is difficult to
declare that a particular lipid is responsible for the penetration of
MCa. Even for the least efficient MCa analogue, MCa K20A,
that interacts only with PtdIns(3)P and sulfatide, there is still
some degree of cell penetration. What seems to differ among all
analogues is not whether these peptides penetrate or not, it is
rather the effective concentration that is required for cell
penetration. This was obvious when comparing the dose–
response curve for cell penetration of the two extreme mutants,
MCa E12A andMCa K20A. It is therefore tempting to conclude
that cell penetration requires both a good affinity for many of
the negatively charged lipids and a wide set of interactions.
Further experimental work will be required to determine the
affinity of MCa for each of the negatively charged lipid
identified here in order to determine whether a particular
correlation may exist between the half-effective concentration
of MCa for penetration and its affinity for some lipids. Also, the
evidence that the penetrated streptavidine appears as punctuate
dots in the cytoplasm of cells may after all indicate a strong
contribution of the interaction of MCa with lipids in a form of
endocytosis. Clarification will be needed on this issue.
Our data indicate that many basic residues of MCa are
involved in the interaction with lipids. The fact that a simple
mutation of some chosen basic residues can so drastically alter
the interaction with some lipids is surprising owing to the fact
2540 K. Mabrouk et al. / Biochimica et Biophysica Acta 1768 (2007) 2528–2540that many other basic residues remain present within MCa.
Nevertheless, these data indicate that amino acid substitution
may thus represent a very interesting alternative to develop
MCa analogues presenting greater affinity for these lipids or
even wider selectivity. Ultimately, this should lead to the
development of analogues of greater potential for cell penetra-
tion. Another surprising finding is that many of the residues that
appear important for an interaction with negatively charged
lipids are also those that are involved in sequence homology
with domain A and in the pharmacological effect of MCa. This
leads to the interesting and unexplored possibility that (i)
domain A may itself interact with negatively lipids adding
complexity to the role of the plasma membrane in the process of
excitation–contraction, and (ii) lipids may competitively favor
or suppress the interaction of MCa or domain Awith its binding
site on RyR. Obviously further work will be required to address
these challenging issues.
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